Candel Therapeutics (NASDAQ:CADL) had its "overweight" rating reaffirmed by analysts at Stephens. They now have a $15.00 price target on the stock.
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 [Yahoo! Finance]
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025
Candel Therapeutics (NASDAQ:CADL) was downgraded by analysts at
Wall Str
Candel Therapeutics (NASDAQ:CADL) had its price target lowered by analysts at Citigroup Inc. from $25.00 to $24.00. They now have a "buy" rating on the stock.